Prevention of emesis from multiple-day and high-dose chemotherapy regimens

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 1, 2007, Pages 51-59

  Navari, Rudolph M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Antiemetics; Chemotherapy induced nausea and vomiting; High dose chemotherapy; Multiple day chemotherapy; Neurokinin 1 receptor antagonists; Serotonin receptor antagonists

Indexed keywords

APREPITANT; AZASETRON; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; GRANISETRON; IRINOTECAN; METOCLOPRAMIDE; OLANZAPINE; ONDANSETRON; PALONOSETRON; RAMOSETRON; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ANTIEMETIC ACTIVITY; CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; HALF LIFE TIME; HUMAN; PRACTICE GUIDELINE; REVIEW; SEDATION; SIDE EFFECT; STEM CELL TRANSPLANTATION; WEIGHT GAIN;

EID: 33846783058     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0007     Document Type: Review

References (79)

1. 3 antagonists. Br J Cancer 1997;76:1055-1061.
2. Lachaine J, Yelle L, Kaizer L, et al. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Supp Cancer Therapy 2005;2:181-187.
3. Osoba D, Zee B, Warr D, et al. Effect of post-chemotherapy nausea and vomiting on health related quality of life. Support Care Cancer 1997;5:307-313.
4. Kris MG. Why do we need another antiemetic? Just ask. J Clin Oncol 2003;21:4077-4080.
5. Hickok JT, Roscoe JA, Morrow GR, et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer 2003;97:2880-2886.
6. Grunsberg SM, Deuson R, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer 2004;100:2261-2268.
7. Berger AM, Clark-Snow RA. Adverse effects of treatment. In: De Vita VT Jr, Helman S, Rosenberg S, eds. Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins, 2001:2869-2880.
8. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-109.
9. Osoba D, Zee B, Pater J, et al. Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 1997;15:116-123.
10. Perez EA. 5-HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res Treat 1999;57:207-214.
11. Hesketh PJ. New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer 2004;12:550-554.
12. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting - two new agents. J Support Oncol 2003;1:89-103.
13. Ettinger DS, Bierman PJ, Bradbury B, et al. The NCCN antiemesis clinical practice guidelines in oncology, version 2, 2006. Available at: http://www.nccn.org/physician_gls/index.html. Accessed October 6, 2006.
14. Multinational Association of Supportive Care in Cancer. Antiemetic guideline consensus. Available at: http://www.mascc.org/ktml2/images/uploads/ Resource_centers/MASCC_Guidelines_Update_9_05.pdf. Accessed October 6, 2006.
15. American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2947.
16. Mantovani G, Maccio A, Bianchi A, et al. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 1996;77:941-948.
17. Simpson K, Spencer CM, McClellan KJ. Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000;59:1297-1315.
18. Kimura E, Niimi S, Watanabe A, et al. [Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]. Gan To Kagaku Ryoho 1996;23:477-481[in Japanese].
19. Taguchi T, Tsukamoto F, Watanabe T, et al. [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]. Gan To Kagaku Ryoho 1999;26:1163-1170.
20. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000;18:163-173.
21. Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-Induced Emesis Prevention Group. J Clin Oncol 1996;14:2242-2249.
22. Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol 1995;13:1242-1248.
23. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann Pharmacother 2003;37:1276-1286.
24. Roila F, Warr D, Clark-Snow RA, et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005;13:104-108.
25. Navari RM, Madajcwicz S, Anderson N, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995;13:2408-2416.
26. Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000;342:1554-1559.
27. Geling O, Eichler H. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289-1294.
28. Hickok JT, Roscoe JA, Morrow GR, et al. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 2005;6:765-772.
29. Herman TS, Einhorn LH, Jones SE, et al. Superiority of nabilone over prochlorperazine as antiemetics in patients receiving cancer chemotherapy. N Engl J Med 1979;300:1295-1297.
30. Einhorn LH, Nagy C, Werner K, Finn AL. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 1990;8:731-735.
31. Sledge GW Jr, Einhorn L, Nagy C, House K. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 1992;70:2524-2528.
32. Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety, and patient preference. The Granisetron Study Group. Eur J Cancer 1994;30A:1083-1088.
33. Fox SM, Einhorn LH, Cox E, et al. Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting aassociated with multiple-day cisplatin chemotherapy. J Clin Oncol 1993;11:2391-2395.
34. Baltzer L, Pisters KMW, Kris MG, et al. High dose ondansetron plus dexamethasone for the prevention of nausea and vomiting with multiple-day cisplatin chemotherapy [abstract]. Proc Am Soc Clin Oncol 1993;12. Abstract 462.
35. Fauser AA, Pizzocaro G, Schueller J, et al. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamthasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer 2000;8:49-54.
36. Handberg J, Wessel V, Larsen L, et al. Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapy. Support Care Cancer 1998;6:63-67.
37. Ondansetron. Lancet 1991;338:753-754. Comments 1991;338:483-490.
38. Einhorn LH, Rapoport B, Koeller J, et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005;13:112-116.
39. Rath U, Upadhyaya BK, Arechavala E, et al. Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 1993;50:168-172.
40. Viner CV, Selby PJ, Zulian GB, et al. Ondansetron - a new, safe, and effective antiemetic in patients receiving high-dose melphalan. Cancer Chemother Pharmacol 1990;25:449-453.
41. Perez EA, Tiemeier T, Solberg LA. Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5HT(3) regimen and literature review. Support Care Cancer 1999;7:414-424.
42. Ballen KK, Hesketh AM, Heyes C, et al. Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant 2001;28:1061-1066.
43. Fox-Geiman MP, Fisher SG, Kiley K, et al. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondasetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplant 2001;7:596-603.
44. Walsh T, Morris AK, Holle LM, et al. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopietic stem cell transplant patients: results of a prospective, double-blind, randomized trial. Bone Marrow Transplant 2004;34:963-968.
45. Matsuoka, S, Okamoto S, Watanabe R, et al. Granisetron plus dexamethasone versus granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Int J Hematol 2003;77:86-90.
46. Abbott B, Ippoliti C, Bruton J, et al. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant 1999;23:265-269.
47. Slaby J, Trneny M, Prochazka B, Klener P. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. Neoplasma 2000;47:319-322.
48. Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 2004;15:330-337.
49. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-2482.
50. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-1577.
51. Aapro M, Grunberg S, Manikhas G, et al. A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemoetherapy. Ann Oncol 2006;17:1441-1449.
52. Cartmell AD, Ferguson S, Yanagihara R, et al. Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5-HT3 receptor antagonist [abstract]. Proc Am Soc Clin Oncol 2003;22:756. Abstract 3041.
53. Barnes MJ, Roth BJ, Dreicer R, et al. Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer [abstract]. Proc Am Soc Clin Oncol 2006;24:494s. Abstract 8607.
54. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60:533-546.
55. Watson JW, Gonsalves SF, Rossa AA, et al. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 1995;115:84-94.
56. Beattie DT, Beresford IJ, Connor HE, et al. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist. Br J Pharmacol 1995;116:3149-3157.
57. Kris MG, Radford JE, Pizzo BA, et al. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin [letter]. J Natl Cancer Inst 1997;89:817-818.
58. Hesketh PJ, Gralla RJ, Webb RT, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999;17:338-343.
59. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 1999;340:190-195.
60. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-2300.
61. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-4119.
62. Poli-Bigelli S, Rogrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-3098.
63. deWit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-4111.
64. Navari RM. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2004;4:715-724.
65. Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004;64:777-794.
66. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17:1000-1006.
67. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
68. Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 2001;430:341-349.
69. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62[suppl 7]:22-31.
70. Hale AS. Olanzapine. Br J Hosp Med 1997;58:442-445.
71. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-443.
72. Jackson WC, Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med 2003;6:251-255.
73. Passik SD, Kirsh KL, Theobald DE, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 2003;25:485-488.
74. Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002;23:526-532.
75. Pirl WT, Roth AJ. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 2000;9:84-87.
76. Srivastava M, Brito-Dellan N, Davis MP, et al. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003;25:578-582.
77. Passik SD, Navari RM, Jung SH, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest 2004;22:383-388.
78. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory. Cancer 2000;89:1634-1646.
79. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005;13:529-534.